623562-56-1

Basic information

• Product Name: 4-[3-(Boc-aMino)propyloxyl]aniline
• Synonyms: 4-[3-(Boc-aMino)propyloxyl]aniline;tert-Butyl (3-(4-aminophenoxy)propyl)carbamate;tert-butyl N-[3-(4-aminophenoxy)propyl]carbamate
• CAS NO: 623562-56-1
• Molecular Formula: C₁₄H₂₂N₂O₃
• Molecular Weight: 266.33608
• Mol File: 623562-56-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-[3-(Boc-aMino)propyloxyl]aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(Boc-aMino)propyloxyl]aniline(623562-56-1)
• EPA Substance Registry System: 4-[3-(Boc-aMino)propyloxyl]aniline(623562-56-1)

Safety Data

• Hazardous Substances Data: 623562-56-1(Hazardous Substances Data)

Upstream product

• 58885-58-8 N-tert-butoxycarbonyl-3-aminopropanol 
• 123-30-8 4-amino-phenol 
• 116861-31-5 tert-butyl N-(3-chloropropyl)carbamate 
• 588-53-4 4-benzylidenamino-phenol 
• 100-02-7 4-nitro-phenol 
• 83948-53-2 3-bromopropylamine tert-butylcarbamate 
• 350-46-9 4-Fluoronitrobenzene 
• 623562-63-0 [3-(4-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1448718-84-0 (S)-3-amino-N-[4-(3-tert-butoxycarbonylamino-propoxy)-phenyl]-succinamic acid tert-butyl ester 
• 1448718-87-3 (S)-N-[4-(3-amino-propoxy)-phenyl]-3-(2-(3-(guanidino)-benzoylamino)-acetylamino)-succinamic acid trifluoroacetate 
• 1448718-88-4 (S)-N-[4-[3-[[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]propoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid 
• 1448718-83-9 (S)-N-[4-(3-tert-butoxycarbonylamino-propoxy)-phenyl]-3-(9H-fluoren-9-ylmethoxycarbonylamino )-succinamic acid tert-butyl ester 

Relevant articles and documents

BIOAVAILABLE PROTEIN DISULFIDE ISOMERASE INHIBITORS

Compounds according to formula (I) are described wherein R1 is an amino acid or a modified amino acid linked to the compound through a peptide bond, R2 is selected from CN, SO2CH3, NO2, CO2R3, CONHR3, NH2, NMe2 and CF3, and R3 is selected from H or lower alkyl, X is O or S, and Y is C-H or N, or a pharmaceutically acceptable salt thereof. The compounds can be used as protein disulfide isomerase inhibitors. The compounds can also be used in a method of treating or cancer in a subject.

Functionalized azobenzene platinum(II) complexes as putative anticancer compounds

The synthesis and characterization of four platinum(II) complexes using azobenzenes conveniently functionalized as ligands has been carried out. The characteristic photochemical behavior of the complexes due to the presence of azobenzene-type ligands and the role of the ligands in the activation of the complexes has been studied. Their promising cytotoxicity observed in HeLa cells prompted us to study the mechanism of action of these complexes as cytostatic agents. The interaction of the compounds with DNA, studied by circular dichroism, revealed a differential activity of the Pt(II) complexes upon irradiation. The intercalation abilities of the complexes as well as their reactivity with common proteins present in the blood stream allows to confirm some of the compounds obtained as good anticancer candidates.

HETEROAROMATIC MACROCYCLIC DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a 2,7-substituted cyano[3,2-d]pyrimidine cyclic compound having protein kinase inhibitory activity, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing, alleviating, or treating a disease caused by abnormal cell growth, which includes the compound as an active ingredient. The novel 2,7-substituted cyano[3,2-d]pyrimidine cyclic compound of the present invention exhibits an excellent effect of inhibiting various protein kinases involved in the signal transduction of growth factors, and thus is effective as an agent for preventing, alleviating, or treating an abnormal cell growth disease caused by these protein kinases.

heteroaromatic macrocyclic derivatives as protein kinase inhibitors

The present invention relates to: a 2,7-substituted cyano[3,2-d]pyrimidine cyclized compound having protein kinase inhibitory activity; a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing, alleviating or treating diseases caused by abnormal cell growth which contains the compound as an active component. A novel 2,7-substituted cyano[3,2-d]pyrimidine cyclized compound of the present invention exhibits excellent inhibitory effects on various protein kinases involved in the growth factor signal transduction, thereby being useful as an agent for preventing, alleviating or treating abnormal cell growth diseases caused by these protein kinases.COPYRIGHT KIPO 2020

OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS

The present invention provides chimeric compounds of formula (II) that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CKl-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.

MACROCYCLES AS KINASE INHIBITORS

Compounds of the formula I in which X, Y, Q1, M, Q2 and B have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3

The invention relates to compounds of formula (I): wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-V-beta-3 integrin antagonists to target cells expressing alpha-V-beta-3.

CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY

The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (α4β1) and alpha-V-beta-3 (αVβ3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides inhibitors of protein kinases of formula I-a and I-b, pharmaceutically acceptable compositions thereof, and methods of using the same.

DIAMINOTHIAZOLES

The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.